Strides Arcolab Gets USFDA Nod to Sell Cancer Drug in US
Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab, has received the US Food and Drug Administration (USFDA) approval to sell the generic version of cisplatin, an anti-cancer injection, in the US market. Cisplatin is a chemotherapy drug used to treat various types of cancers.
Strides Arcolab Ltd is a major Indian pharmaceutical company that manufactures a wide range of pharmaceutical products, including softgel capsules, sterile injectables and others. Strides Arcolab said in a statement that it has received the approval to market cisplatin injection in the strength of 1 mg/ml in 50ml and 100ml multiple dose vials. The company also reported that the approval of cisplatin has come at just the right time when the US drug market is facing shortage of the chemotherapy drugs.
"Cisplatin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market," Strides Arcolab said in a release. The company also added that it expects to launch the product shortly in the US market. According to the data from the India's largest pharmaceutical intelligence and market research company, the annual sale of generic cisplatin in the US is 10 million USD.